Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

75
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
75
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.0K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.0K
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

74
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
74
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

71
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
71
Allergic Drug Reactions01:27

Allergic Drug Reactions

1.5K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.5K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

3.6K
The pathophysiology of pneumonia involves the following steps:
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of Rehabilitation Utilization After CAR T-Cell Therapy.

Transplantation and cellular therapy·2026
Same author

Real-World Experience With a ZUMA-1 Cohort 4 Adopted Approach to CRS and ICANS in CAR-T Recipients.

European journal of haematology·2026
Same author

Preventing trogocytosis by cathepsin B inhibition augments CAR T-cell function.

Signal transduction and targeted therapy·2026
Same author

Faecal microbiota transplant for chronic norovirus infection: a case report of donor microbiota engraftment without clinical success.

Gastroenterology report·2026
Same author

Comprehensive Assessment of CD19 Immunohistochemical Staining in Classic Hodgkin Lymphoma.

The American journal of surgical pathology·2026
Same author

Surgical resection of pleural lipoma after 9 years of serial imaging.

Journal of cardiothoracic surgery·2026
Same journal

Chronic Expanding Hematoma Complicated by Life Threatening Hemoptysis and Respiratory Arrest-A Case Report.

Respirology case reports·2026
Same journal

Initial Dose Tarlatamab-Associated Tumour Lysis Syndrome in Small Cell Lung Cancer: A Case Report.

Respirology case reports·2026
Same journal

EBUS-Guided Incidental Finding of Pulmonary Vein Thrombosis: A Case Report and Literature Review.

Respirology case reports·2026
Same journal

First Case of Acute Pleural Empyema Caused by <i>Mediterraneibacter gnavus</i>.

Respirology case reports·2026
Same journal

A Case of Disseminated Nocardiosis due to <i>Nocardia otitidiscaviarum</i> With Pulmonary Infection and a Thyroid Abscess.

Respirology case reports·2026
Same journal

Usual Interstitial Pneumonia in a Patient With Celiac Disease: Expanding the Spectrum of Pulmonary Manifestations.

Respirology case reports·2026
See all related articles

Related Experiment Video

Updated: Mar 3, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K

Lenalidomide-induced eosinophilic pneumonia.

Andrew Toma1, Aaron P Rapoport2, Allen Burke3

  • 1FAU College of Medicine Boca Raton FL USA.

Respirology Case Reports
|April 29, 2017
PubMed
Summary
This summary is machine-generated.

A rare case of eosinophilic pneumonia developed in a multiple myeloma patient treated with lenalidomide. This drug-induced lung condition resolved upon lenalidomide withdrawal, highlighting the importance of considering medication toxicity.

Keywords:
Eosinophilialenalidomidelung injury

More Related Videos

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
08:44

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

6.6K
Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

1.5K

Related Experiment Videos

Last Updated: Mar 3, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K
Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
08:44

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

6.6K
Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

1.5K

Area of Science:

  • Hematology
  • Pulmonology
  • Clinical Pharmacology

Background:

  • Multiple myeloma is a significant hematologic malignancy.
  • Lenalidomide, an immunomodulatory drug, is used for myelodysplastic syndrome and multiple myeloma.
  • Pulmonary side effects of lenalidomide are considered uncommon.

Observation:

  • A patient with relapsed multiple myeloma developed eosinophilic pneumonia after lenalidomide treatment post-autologous stem cell transplant.
  • Symptoms included dyspnea, peripheral eosinophilia, and bilateral pulmonary opacities.
  • Infection was ruled out via bronchoscopy and bronchoalveolar lavage.

Findings:

  • Transbronchial lung biopsies confirmed eosinophilic pneumonia.
  • Discontinuation of lenalidomide and initiation of prednisone led to symptom improvement and eosinophilia resolution.
  • Recurrence of symptoms upon readministration of lenalidomide confirmed the drug's causative role.

Implications:

  • This case highlights lenalidomide-induced eosinophilic pneumonia as a potential adverse effect.
  • Clinicians should consider drug toxicity in the differential diagnosis of pulmonary symptoms in patients receiving lenalidomide.
  • Early recognition and management of drug-induced lung disease are crucial for patient outcomes.